



Devicare signs a 2 million Euro participative loan from Avançsa's Innova Global line

With this new economic injection, the company will continue the strategic development and validation plan for new medical solutions under the Remote Patient Monitoring concept

Cerdanyola del Vallès (Barcelona), 22 December 2017 – Devicare has signed a participative loan worth 2 million Euros from the **Innova Global line** by Avançsa, assigned to the Business and Expertise Department, with the option to convert the investment into Series A stock in the mid-term.

With this new economic injection, Devicare will continue the **strategic development and validation plan** of **new medical solutions** under the Remote Patient Monitoring concept, which simply and economically places patients at the centre of their own healthcare management, known as patient empowerment, as well as the corresponding clinical studies and trials for the **expansion throughout the European and North American markets**.

Francisco Cabezas, the company's financial director, explains that "we have left the start-up phase behind. We're now completely in the validation phase with a **business model that perfectly fits Avançsa's strategic objectives**: an entrepreneurial project with an extremely innovative component and an excellent potential for international expansion, impact in the territory and feasibility."

Sensor technology for multiple medical fields

Devicare is developing a patented technology using sensors to measure biometrics in breath and body fluids such as blood, sweat, saliva and urine which can be exported for the prevention and treatment of different diseases. At present the company's experience has focused on recurring urological diseases (Lit-Control®) and patients using anticoagulants (Tao-Control®), but the company is now collaborating with renowned centres and hospitals in Catalonia to resolve uncovered medical needs.

....

About Devicare

Devicare (<http://www.devicare.com/en/>) is a company specialized in the development of innovative solutions and medical devices for the home care of chronic patients. These



solutions are developed under the concept of Remote Patient Monitoring (RPM) in order to enable the patient to actively participate in the monitoring of their disease. Currently, the company offers two product lines: Lit-Control® (www.lit-control.com) for the prevention and self-management of recurrent urinary diseases and Tao-Control® (www.tao-control.com) for self-management of patients taking anticoagulants (medicines such as Sintrom® or Aldocumar®). Devicare's headquarters is located at the UAB Research Park, in Cerdanyola del Vallès, near Barcelona (Spain).

Further information:

Devicare

Gemma Escarré (Communications Manager)

M. 667 76 15 24

gescarre@devicare.com